EUCTR2005-002536-94-ES进行中（未招募）不适用
Estudio multicéntrico en fase III, aleatorizado, doble ciego, de grupos paralelos y control activo, para evaluar la eficacia y la seguridad de dabigatran etexilato oral (150 mg bid) en comparación con warfarina (INR 2.0-3.0) para la prevención secundaria del tromboembolismo venoso. RE-MEDY. - RE-MEDY
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 2,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Objectively confirmed symptomatic uni- or bilateral DVT of the leg involving proximal veins or PE, treated with approved anticoagulant therapy, or with study drug taken during participation in trial 1160.53, for 3 to 6 months at the time of screening, in patients considered at increased risk of recurrent VTE [proximal veins are: trifurcation area, popliteal, superficial femoral, deep femoral, common femoral and iliac vein]
- •2. Male or female, being 18 years of age or older
- •3. Written informed consent for study participation
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Symptomatic DVT or PE at screening
- •2. Patients with primary PE with suspected origin other that leg limbs (e.g. upper limbs, right heart).
- •3. Actual or anticipated use of vena cava filter
- •4. Interruption of anticoagulant therapy for 2 or more weeks during the 3-6 months of treatment for the prior VTE.
- •5. Patients who in the investigator’s opinion should not be treated with warfarin
- •6. Allergy to warfarin or dabigatran, or to one of the excipients included in these medications
- •7. Patients who in the investigator’s judgement are perceived as having an excessive risk of bleeding
- •8. Known anaemia (haemoglobin < 100 g•L-1)
- •9. Need of anticoagulant treatment for disorders other than VTE
- •10. Recent unstable cardiovascular disease, such as uncontrolled hypertension at the time of enrolment (investigator’s judgement), acute bacterial endocarditis or history of myocardial infarction within the last 3 months
- •11. Elevated AST or ALT > 2x ULN based on the local lab results obtained at screening and prior to randomisation (or central screening lab if available on time)
- •12. Liver disease expected to have any potential impact on survival (e.g. acute hepatitis, or possibly active hepatitis B, hepatitis C or cirrhosis, but not Gilbert’s syndrome or hepatitis A with complete recovery)
- •13. Patients who have developed transaminase elevations upon exposure to ximelagatran
- •14. Severe renal impairment (estimated creatinine clearance = 30 ml/min)
- •15. Women who are pregnant, nursing or of childbearing potential who refuse to use a medically acceptable form of contraception throughout the study (NOTE: A negative pregnancy test must be obtained for any woman of childbearing potential prior to entry into the study)
- •16. Participation in another clinical trial with an investigational drug during the last 30 days, except for the RE-COVER trial, or previous participation in this study
- •17. Patients considered unsuitable for inclusion by the investigator, e.g. because considered unreliable to comply with the requirements for follow-up during the study and/or compliance with study drug administration, has a life expectancy less than the expected duration of the trial due to concomitant disease, or has any condition which in the opinion of the investigator would not allow safe participation in the study (e.g., drug addiction, alcohol abuse)
- •18. In case of anticipated study related diagnostic procedures requiring contrast medium
- •(e.g. contrast venography or pulmonary angiography):
- •Elevated serum creatinine, which in the investigator’s opinion contraindicates these examinations
- •Known allergy to radio opaque contrast media or iodine, which in the investigator’s opinion contraindicates these examinations
研究者
相似试验
进行中（未招募）
1 期
Estudio de fase III multicéntrico, aleatorizado, doble ciego, y controlado con placebo sobre la eficacia de Xaliproden para prevenir la neurotoxicidad de Oxaliplatino en el tratamiento de primera línea de pacientes con cáncer colorrectal metastático tratados con Oxaliplatino/5-FU/LV.EUCTR2005-002570-30-ESSanofi-Synthelabo Recherche900
进行中（未招募）
不适用
Estudio de fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la seguridad y la eficacia de MK-4305 en pacientes con insomnio primario -Estudio B ;A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of MK-4305 in Patients with Primary Insomnia- Study BInsomnio Primario /Primary InsomniaMedDRA version: 11Level: LLTClassification code 10036701Term: Insomnio primarioEUCTR2010-018414-69-ESMerck & Co., Inc.945
进行中（未招募）
1 期
Estudio de fase III, multicéntrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo, para evaluar la eficacia y seguridad del agonista beta-3 YM178 (25 mg, una vez al día y 50 mg, una vez al día) en pacientes con síntomas de vejiga hiperactiva.A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (25 mg qd and 50 mg qd) in Subjects with Symptoms of Overactive Bladder - CAPRICOREUCTR2008-007087-42-ESAstellas Pharma Europe B.V.1,300
进行中（未招募）
1 期
Estudio de fase III, multicéntrico, aleatorizado, doble ciego y con dosis múltiples de Alpharadin en el tratamiento de pacientes con cáncer de próstata hormonorefractario y metástasis óseas - Not ApplicableCáncer de próstata hormonorefractario con metástasis óseasMedDRA version: 9.1Level: LLTClassification code 10027452Term: Metastases to boneEUCTR2007-006195-11-ESAlgeta ASA921
进行中（未招募）
不适用
Estudio de fase III, multicéntrico, aleatorizado, de grupos paralelos, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de ocrelizumab en adultos con esclerosis múltiple progresiva primaria A Phase III, multicenter, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis - OratorioEsclerosis múltiple progresiva primaria (EMPP)MedDRA version: 12.1Level: LLTClassification code 10063401Term: Primary progressive multiple sclerosisEUCTR2010-020338-25-ESF.Hoffmann-La Roche630